SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May-July 2021.

2019 novel coronavirus disease 2019 novel coronavirus infection 2019-nCoV COVID-19 Colorado SARS-CoV-2 SARS-CoV-2 infection United States antibody testing coronavirus disease diagnostic testing pandemic respiratory infections serologic testing severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
05 2023
Historique:
medline: 21 4 2023
pubmed: 28 3 2023
entrez: 27 3 2023
Statut: ppublish

Résumé

To compare SARS-CoV-2 antibody seroprevalence among children with seropositive confirmed COVID-19 case counts (case ascertainment by molecular amplification) in Colorado, USA, we conducted a cross-sectional serosurvey during May-July 2021. For a convenience sample of 829 Colorado children, SARS-CoV-2 seroprevalence was 36.7%, compared with prevalence of 6.5% according to individually matched COVID-19 test results reported to public health. Compared with non-Hispanic White children, seroprevalence was higher among Hispanic, non-Hispanic Black, and non-Hispanic other race children, and case ascertainment was significantly lower among Hispanic and non-Hispanic Black children. This serosurvey accurately estimated SARS-CoV-2 prevalence among children compared with confirmed COVID-19 case counts and revealed substantial racial/ethnic disparities in infections and case ascertainment. Continued efforts to address racial and ethnic differences in disease burden and to overcome potential barriers to case ascertainment, including access to testing, may help mitigate these ongoing disparities.

Identifiants

pubmed: 36972709
doi: 10.3201/eid2905.221541
pmc: PMC10124638
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

929-936

Références

MMWR Morb Mortal Wkly Rep. 2021 Mar 05;70(9):312-315
pubmed: 33661862
Pediatr Clin North Am. 2021 Oct;68(5):1133-1145
pubmed: 34538304
Inflamm Bowel Dis. 2021 Oct 20;27(11):1862-1864
pubmed: 34427638
JAMA Pediatr. 2022 Nov 1;176(11):1142-1143
pubmed: 36036929
Curr Opin Pediatr. 2021 Feb 1;33(1):114-121
pubmed: 33278112
Arch Pathol Lab Med. 2021 May 1;145(5):536-542
pubmed: 33461214
Pediatrics. 2021 Jan;147(1):
pubmed: 33115793
Lancet Child Adolesc Health. 2021 Oct;5(10):708-718
pubmed: 34358472
Sci Adv. 2021 Jul 30;7(31):
pubmed: 34330709
Public Health Rep. 2022 Jan-Feb;137(1):128-136
pubmed: 34752156
Pathology. 2020 Dec;52(7):801-808
pubmed: 32888706
JAMA Pediatr. 2021 Jun 1;175(6):586-593
pubmed: 33480966
Clin Infect Dis. 2021 Dec 16;73(12):2366-2368
pubmed: 33693643
Eur J Epidemiol. 2021 Jul;36(7):715-725
pubmed: 34420152
Health Place. 2021 May;69:102576
pubmed: 33915376
Emerg Infect Dis. 2021 Sep;27(9):2454-2458
pubmed: 34193339
Clin Infect Dis. 2020 Dec 3;71(9):2469-2479
pubmed: 32392337
Microbiol Spectr. 2021 Oct 31;9(2):e0073121
pubmed: 34523985
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Sci Rep. 2021 Jul 6;11(1):13903
pubmed: 34230530
BMC Med. 2022 Oct 13;20(1):379
pubmed: 36224590
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Pediatrics. 2020 Oct;146(4):
pubmed: 32759379
Pediatr Infect Dis J. 2021 Apr 1;40(4):e157-e159
pubmed: 33427800
Open Forum Infect Dis. 2022 Jan 30;9(3):ofac044
pubmed: 35198651
Ital J Pediatr. 2021 Jun 5;47(1):131
pubmed: 34090486
JAMA Netw Open. 2022 Mar 1;5(3):e221313
pubmed: 35262717
JAMA Pediatr. 2021 Sep 1;175(9):928-938
pubmed: 34152371
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Dec;64(12):1483-1491
pubmed: 34731291
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
BMC Public Health. 2014 Feb 11;14:147
pubmed: 24517715
JAMA. 2021 Oct 12;326(14):1400-1409
pubmed: 34473201
JAMA Netw Open. 2021 Nov 1;4(11):e2135975
pubmed: 34812845
Pediatr Infect Dis J. 2020 Jun;39(6):469-477
pubmed: 32398569

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH